: FTC settles with Amgen over $27.8 billion takeover of Horizon Therapeutics

The Federal Trade Commission reached a deal with Amgen Inc. AMGN to approve its $27.8 billion acquisition of Horizon Therapeutics plc, HZNP the agency announced Friday. Under the deal. Amgen will be barred from bundling existing products with Horizon’s Tepezza or Krystexxa, two drugs used to treat thyroid eye disease and chronic refractory gout, respectively.Amgen will also have to get approval from the FTC to acquire any products that treat those diseases. As part of the deal, attorneys general for California, Illinois, Minnesota, New York, Washington, and Wisconsin have also agreed to dismiss their federal suits seeking to block the merger.

Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.